• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22896 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2013     NIHR Horizon Scanning Centre (NIHR HSC) Ticagrelor (Brilique) for secondary prevention of cardiovascular disease events in patients with prior myocardial infarction
2016     National Institute for Health and Care Excellence (NICE) Ticagrelor for preventing atherothrombotic events after myocardial infarction. NICE technology appraisal guidance 420
2019     Agency for Care Effectiveness (ACE) Ticagrelor for preventing thrombotic events in adults with acute coronary syndromes
2011     NIHR Health Technology Assessment programme Ticagrelor for the treatment of acute coronary syndromes
2011     National Institute for Health and Care Excellence (NICE) Ticagrelor for the treatment of acute coronary syndromes. NICE technology appraisal guidance 236
2007     Institute for Clinical Effectiveness and Health Policy (IECS) Tigecycline: usefulness of its clinical application
2015     NIHR Horizon Scanning Centre (NIHR HSC) Tildrakizumab for moderate to severe plaque psoriasis
2019     National Institute for Health and Care Excellence (NICE) Tildrakizumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 575
2001     Centre for Clinical Effectiveness (CCE) Time to commencement of oral feeding following laryngectomy
2008     NIHR Health Technology Assessment programme Time to full publication of studies of anti-cancer medicines for breast cancer, and the potential for publication bias: a short systematic review
2008     NIHR Health Technology Assessment programme Time to full publication of studies of anti-cancer medicines for breast cancer, and the potential for publication bias: a short systematic review
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Timing of antibiotic therapy for neisseria gonorrhoeae infection
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Timing of enoxaparin administration for the prophylaxis of venous thromboembolism: clinical evidence and guidelines
2017     NIHR Health Technology Assessment programme Timing of surgical intervention for developmental dysplasia of the hip: a randomised controlled trial (Hip 'Op)
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Timing of umbilical cord clamping for neonatal and maternal outcomes
2019     Penn Medicine Center for Evidence-based Practice (CEP) Timing of valve replacement for patients with infective endocarditis and intracranial embolism
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Timothy grass standardized allergenic extract (Grastek — Merck Canada Inc.) indication: allergic rhinitis (grass pollen)
1999     Alberta Heritage Foundation for Medical Research (AHFMR) Tin-117m DTPA
2022     WorkSafeBC Tinnitus and the COVID-19 vaccine
1998     Wessex Institute for Health Research and Development (WIHRD) Tinnitus retraining therapy
2004     Washington State Department of Labor and Industries (WSDLI) Tinnitus retraining therapy
2004     WorkSafeBC Tinnitus retraining therapy
2010     Canadian Agency for Drugs and Technologies in Health (CADTH) Tinnitus retraining therapy: a review of the clinical effectiveness
2015     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tinzaparin sodium (Innohep®)
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Tinzaparin versus dalteparin or enoxaparin for the treatment of venous thromboembolism in adults: safety and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Tiotropium bromide
2002     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Tiotropium bromide
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness
2012     Canadian Agency for Drugs and Technologies in Health (CADTH) Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness
2001     NIHR Horizon Scanning Centre (NIHR HSC) Tiotropium for COPD - horizon scanning review
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Tiotropium for moderate-to-severe chronic obstructive pulmonary disease: a review of the clinical effectiveness and cost-effectiveness
2009     Belgian Health Care Knowledge Centre (KCE) Tiotropium in the treatment of chronic obstructive pulmonary disease health technology assessment
2009     Belgian Health Care Knowledge Centre (KCE) Tiotropium in the treatment of chronic obstructive pulmonary disease: health technology assessment
2002     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Tiotropium: a potential replacement for ipratropium in patients with COPD
2019     Penn Medicine Center for Evidence-based Practice (CEP) Tip positioning of short-term central venous catheters
2007     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tipranavir (Aptivus®)
2010     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tipranavir (Aptivus®) capsules
2010     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tipranavir (Aptivus®) oral solution
2002     NIHR Horizon Scanning Centre (NIHR HSC) Tirapazamine for non-small cell lung cancer - horizon scanning review
2023     National Institute for Health and Care Excellence (NICE) Tirzepatide for treating type 2 diabetes. NICE technology appraisal guidance 924
2022     Institute for Clinical and Economic Review (ICER) Tirzepatide for type 2 diabetes
2019     Canadian Agency for Drugs and Technologies in Health (CADTH) Tisagenlecleucel for acute lymphoblastic leukemia and diffuse large b-cell lymphoma: clinical report
2022     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal). NICE technology appraisal guidance 842
2018     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. NICE technology appraisal guidance 554
2023     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal). NICE technology appraisal guidance 933
2019     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies. NICE technology appraisal guidance 567
2008     HAYES, Inc. Tisseel VH (Baxter Healthcare Corp.) for cardiac surgery
2008     HAYES, Inc. Tisseel VH (Baxter Healthcare Corp.) for noncardiac surgeries with problematic hemostasis
2008     HAYES, Inc. Tissue doppler imaging for cardiomyopathy
2002     NIHR Horizon Scanning Centre (NIHR HSC) Tissue engineered heart valves - horizon scanning review
2015     HAYES, Inc. Tissue of Origin Test (ResponseDX)
2007     National Institute for Health and Care Excellence (NICE) Tissue-cultured limbal stem cell allograft transplantation for regrowth of corneal epithelium
2005     Institute for Clinical Systems Improvement (ICSI) Tissue-type plasminogen activator for acute ischemic stroke
2012     Malaysian Health Technology Assessment (MaHTAS) Titanium dioxide photocatalyst coatings
2011     HAYES, Inc. title
2011     NIHR Horizon Scanning Centre (NIHR HSC) Tivozanib for renal cell cancer, locally advanced or metastatic - first line
2018     National Institute for Health and Care Excellence (NICE) Tivozanib for treating advanced renal cell carcinoma. NICE technology appraisal guidance 512
2023     National Institute for Health and Care Excellence (NICE) Tixagevimab plus cilgavimab for preventing COVID-19. NICE technology appraisal guidance 900
2013     NIHR Horizon Scanning Centre (NIHR HSC) TK cell therapy for acute leukaemia patients who are candidate to haematopoietic stem cell transplantation – adjunct therapy
2001     Blue Cross Blue Shield Association (BCBS) TMR as an adjunct to CABG surgery for the treatment of coronary artery disease
2006     Norwegian Knowledge Centre for the Health Services (NOKC) TNF-inhibitors in rheumatoid diseases
1999     TNO To the infrastructure of efficient information over medical devices
2003     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) Tobacco control: a review of the strategies
2002     The Swedish Council on Health Technology Assessment (SBU) Tobacco smoking and oral health
2006     Agency for Healthcare Research and Quality (AHRQ) Tobacco use: prevention, cessation, and control
2015     Institute for Clinical Effectiveness and Health Policy (IECS) Tobramycin inhalation powder versus Tobramycin inhalation solution for cystic fibrosis
2010     NIHR Horizon Scanning Centre (NIHR HSC) Tobramycin inhaled powder (TIP) for Pseudomonas aeruginosa infection in cystic fibrosis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Tocilizumab (Actemra - Hoffmann-La Roche Limited) new indication: polyarticular juvenile idiopathic arthritis
2006     NIHR Horizon Scanning Centre (NIHR HSC) Tocilizumab (actemra) for rheumatoid arthritis and juvenile idiopathic arthritis: horizon scanning review
2012     NIHR Horizon Scanning Centre (NIHR HSC) Tocilizumab (RoActemra) for active polyarticular juvenile idiopathic arthritis – second line
2011     NIHR Horizon Scanning Centre (NIHR HSC) Tocilizumab (RoACTEMRA) for early rheumatoid arthritis not treated with methotrexate – first line
2011     NIHR Horizon Scanning Centre (NIHR HSC) Tocilizumab (RoACTEMRA) for early rheumatoid arthritis not treated with methotrexate – first line
2014     NIHR Horizon Scanning Centre (NIHR HSC) Tocilizumab (RoACTEMRA) for giant cell arteritis – first and second line
2014     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tocilizumab (RoActemra®)
2010     Institute for Clinical Effectiveness and Health Policy (IECS) Tocilizumab for rheumatoid arthritis
2021     European Network for Health Technology Assessment (EUnetHTA) Tocilizumab for the treatment of COVID-19
2009     NIHR Health Technology Assessment programme Tocilizumab for the treatment of rheumatoid arthritis
2010     National Institute for Health and Care Excellence (NICE) Tocilizumab for the treatment of rheumatoid arthritis
2012     National Institute for Health and Care Excellence (NICE) Tocilizumab for the treatment of rheumatoid arthritis. NICE technology appraisal guidance 247
2011     NIHR Health Technology Assessment programme Tocilizumab for the treatment of systemic juvenile idiopathic arthritis
2011     National Institute for Health and Care Excellence (NICE) Tocilizumab for the treatment of systemic juvenile idiopathic arthritis. NICE technology appraisal guidance 238
2018     National Institute for Health and Care Excellence (NICE) Tocilizumab for treating giant cell arteritis. NICE technology appraisal guidance 518
2009     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Tocolysis in preterm labour - a systematic review of evidence-based guidelines, effectiveness and health economic evaluations
2000     Institute for Clinical Systems Improvement (ICSI) Tocolytic therapy for preterm labor
2015     NIHR Horizon Scanning Centre (NIHR HSC) Tofacitinib for chronic plaque psoriasis – second line
2014     NIHR Horizon Scanning Centre (NIHR HSC) Tofacitinib for moderate to severe active ulcerative colitis
2012     NIHR Horizon Scanning Centre (NIHR HSC) Tofacitinib for moderate to severe chronic plaque psoriasis – second line
2017     National Institute for Health and Care Excellence (NICE) Tofacitinib for moderate to severe rheumatoid arthritis. NICE technology appraisal guidance 480
2018     National Institute for Health and Care Excellence (NICE) Tofacitinib for moderately to severely active ulcerative colitis. NICE technology appraisal guidance 547
2015     NIHR Horizon Scanning Centre (NIHR HSC) Tofacitinib for psoriatic arthritis – second or subsequent line
2023     National Institute for Health and Care Excellence (NICE) Tofacitinib for treating active ankylosing spondylitis. NICE technology appraisal guidance 920
2018     National Institute for Health and Care Excellence (NICE) Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 543
2021     National Institute for Health and Care Excellence (NICE) Tofacitinib for treating juvenile idiopathic arthritis. NICE technology appraisal guidance 735
2022     Agency for Care Effectiveness (ACE) Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease
2022     Agency for Care Effectiveness (ACE) Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease
2006     NIHR Horizon Scanning Centre (NIHR HSC) Tolevamer for clostridium difficile associated diarrhea: horizon scanning review
2012     NIHR Horizon Scanning Centre (NIHR HSC) Tolvaptan for autosomal dominant polycystic kidney disease
2007     NIHR Horizon Scanning Centre (NIHR HSC) Tolvaptan for heart failure (NYHA): horizon scanning technology briefing
2015     National Institute for Health and Care Excellence (NICE) Tolvaptan for treating autosomal dominant polycystic kidney disease. NICE technology appraisal guidance 358
2009     Adelaide Health Technology Assessment (AHTA) TomoTherapy HI-ART System radiotherapy planning and treatment for cancer